echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Which enterprises in the 4 + 7 volume purchase list are likely to lose / gain the most?

    Which enterprises in the 4 + 7 volume purchase list are likely to lose / gain the most?

    • Last Update: 2018-11-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Last week, the 4 + 7 urban volume procurement document was issued, which attracted wide attention in the industry Which companies are most affected? The new health sector combed out the pharmaceutical companies with the greatest possible loss / benefit for the readers On November 21, the Shanghai Municipal Administration of pharmaceutical centralized bidding and purchase Affairs issued the supplementary document of 4 + 7 urban pharmaceutical centralized purchase in Shanghai area, which set a new threshold for the quality of consistency evaluation It is required that each batch of drugs must be monitored by near-infrared spectrum modeling and other detection methods after the application of drugs for selection, so as to ensure the stable and consistent quality of drugs before and after the selection, and must be accepted Spot check at least twice a year and flight inspection if necessary According to the purchase documents, the medical institutions in Shanghai can continue to purchase and use the drugs not selected on the premise of ensuring the quantity of the selected varieties, but the quantity shall not exceed the selected varieties after conversion according to the proportion relationship It is worth mentioning that the highest price drugs of the same variety that are not selected in the centralized purchase declaration must be purchased and used on the basis of the 2017 bidding price (or online price) of the city, and the gradient price reduction (based on the bottom price of the selected price) can be realized according to the price difference, and the price reduction range shall be further increased for those with large price difference In other words, to win the bid, the product price must be lower than the lowest purchase price of the same product of the enterprise in the pilot area at the end of 2017 Which companies are most affected? The new health sector combed out the pharmaceutical companies with the greatest possible loss / benefit for the readers Referring to the bid winning price of the original research drug of foreign enterprises, it is found that Pfizer, Sanofi, Lilly, Squibb and AstraZeneca are the five enterprises most affected If the product bidding fails, the loss amount can reach one billion level 1 Pfizer: 3.12 billion Pfizer's products entering the 4 + 7 catalog are atorvastatin calcium tablets, amlodipine besylate tablets, Azithromycin Capsules, azithromycin tablets and azithromycin for injection, involving a total purchase amount of 3.12 billion Among them, the purchase amount of atorvastatin oral regular release dosage form 10mg is 87.2436 million tablets, and the purchase amount of 20mg is 156.7218 million tablets The scale involved is estimated to be 1.65 billion yuan by the bid price The purchase volume of amlodipine oral regular release dosage form is 293.8202 million tablets, and the expected purchase scale is 1.25 billion yuan The purchase quantity of azithromycin oral regular release dosage form is 250mg, 20391500 tablets, 500mg, 79400 tablets, 380300 azithromycin injections, with a total scale of 220 million 2 Sanofi: 1.68 billion Sanofi products related to 4 + 7 procurement catalogue mainly include irbesartan tablets, irbesartan hydrochlorothiazide tablets and clopidogrel bisulfate tablets The reported dosage of irbesartan is 44.3242 million tablets of 75mg and 93.1151 million tablets of 150mg, with a total procurement scale of 380 million The reported dosage of irbesartan hydrochlorothiazide is 92.156 million tablets, and the procurement scale is estimated to be 390 million The reported dosage of clopidogrel 75 mg was 57.4659 million tablets, with a total procurement scale of 0.97 billion If Sanofi's products entered the 4 + 7 catalog are calculated according to the original research price, the purchase amount involved is 1.68 billion 3 Lilly: 1.14 billion yuan of Lilly's products mainly include pemetrexed disodium for injection, olanzapine tablets, 10 mg 10.4736 million tablets of olanzapine, 5 mg 17.8347 million tablets of olanzapine, corresponding purchase amount of 760 million yuan Pemetrexed has 100mg39100 injections and 500mg2 2900 injections, with the corresponding purchase amount of 380 million yuan 4 Bristol Myers Squibb: 1.13 billion yuan The only product that Bristol Myers Squibb enters the catalog is entecavir 0.5mg of entecavir was reported to be 41.3351 million tablets, with a purchase amount of 1.13 billion yuan 5 AstraZeneca: a total of 960 million yuan of AstraZeneca's 4 + 7 products include rosuvastatin calcium tablets, gefitinib tablets and lisinopril tablets The purchase amount of rosuvastatin oral regular release dosage form 10mg is 82857000 tablets, 5mg is 60069700 tablets, involving the purchase amount of 830 million yuan The purchase amount of gefitinib oral regular release dosage form is 491500 tablets, involving 120 million yuan The purchase amount of lisinopril oral regular release dosage form is 2.0871 million tablets, 5 mg is 226200 tablets, and the domestic scale is not more than 10 million AstraZeneca's total purchase amount is RMB 960 million For domestic enterprises, taking the lowest purchase price of the same product in the pilot area at the end of 2017 as a reference, three enterprises such as Zhengda Tianqing, Zhejiang xindonggang / Beijing Jialin and xinlitai may have the greatest impact 1 Zhengda Tianqing: 1.15 billion yuan of Zhengda Tianqing's products are entecavir, tenofovir dipivoxil, irbesartan hydrochlorothiazide and rosuvastatin 0.5mg of entecavir was reported as 41.3351 million tablets, involving 480 million yuan The dosage of irbesartan hydrochlorothiazide was 150mg / 12.5mg and 92.156 million tablets were reported, involving 230 million yuan The dosage of rosuvastatin 10mg was 82857000 tablets, involving 330 million yuan The dosage of tenofovir dipivoxil 300mg was 6.2182 million tablets, involving 100 million yuan Zhengda Tianqing is expected to involve 1.15 billion yuan in procurement As more than three manufacturers of the above products enter the conformity assessment, it is expected that the procurement scale will decline 2 Zhejiang Xindong port / Beijing Jialin: RMB 1.09 billion, Zhejiang Xindong port / Beijing Jialin is ranked mainly by atorvastatin 10 mg of atorvastatin oral regular release dosage form involves 87.2436 million tablets, 20 mg involves 156.7218 million tablets, and the expected procurement scale is 1.09 billion The size of this scale depends on the final bidding of Zhejiang xindonggang and Beijing Jialin 3 Xinlitai: with a product of clopidogrel, xinlitai also entered the ranking with an amount of 830 million yuan The dosage of clopidogrel was 183.2056 million tablets (25mg) and 57.4659 million tablets (75mg), with a total procurement scale of 830 million 25mg is the exclusive specification, 75mg is bidding with original research, and the final scale of xinlitai depends on the average decline of more than three manufacturers 4 Yangtze River: there are five products in the Yangtze River with a total value of 740 million yuan, including amlodipine, montmorillonite, enalapril, enalapril and dextromethoridine Among them, amlodipine is 590 million yuan, dextromethomidine is 110 million yuan, and other products are less than 100 million yuan, with an estimated total of 740 million yuan 15 Huahai: of the 600 million yuan domestic enterprises, Huahai pharmaceutical industry has the largest number of products in the 4 + 7 catalog, including six varieties of irbesartan, irbesartan hydrochlorothiazide, fosinopril, lisinopril, risperidone, losartan and paroxetine, involving about 600 million yuan, not in the top three Among them, the largest variety is irbesartan hydrochlorothiazide, with a purchase amount of 240 million yuan, followed by losartan (220 million yuan).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.